Inhibition of TAMs is of substantial interest as there is evidence that macrophages adopt a phenotype that promotes tumor growth, angiogenesis, invasion, and metastasis when they enter the tumor microenvironment34; consequently, there are numerous TAM inhibitors in clinical development, including inhibitors of CSF1 or CSF1R aimed at sensitizing tumors to the effects of other immunotherapies.35 This evidence concerns the gene CSF1R and neoplasm.